Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navacaprant - Neumora Therapeutics

Next Previous
Drug Profile

Navacaprant - Neumora Therapeutics

Alternative Names: BTRX-140; BTRX-335140; CYM-53093; Navacaprant; NMRA-140; NMRA-335140

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BlackThorn Therapeutics
  • Developer Neumora Therapeutics
  • Class Amines; Antidepressants; Anxiolytics; Behavioural disorder therapies; Fluorinated hydrocarbons; Mood stabilisers; Oxadiazoles; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Major depressive disorder
  • Phase II Bipolar depression

Most Recent Events

  • 12 May 2025 Efficacy data from the phase III KOASTAL-2 trial in Major depressive disorder released by Neumora Therapeutics
  • 15 Jan 2025 Neumora Therapeutics completes phase III KOASTAL-1 trial in Major depressive disorder in USA (PO) (NCT06029426)
  • 02 Jan 2025 Efficacy and adverse events data from the phase III trial in Major depressive disorder released by Neumora Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top